CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

The Next Frontier of U=U Science

Undetectable equals untransmittable (U=U) has improved HIV prevention and tackled stigma, but there are still a few questions to answer.

By Sony Salzman

CDC Explains and Defends Molecular Surveillance System

A leading researcher at the Centers for Disease Control and Prevention addressed community concerns that surveillance data will be used to put people in prison under HIV criminalization laws.

By Martha Kempner

'Drug Users Are People Too': Addressing Opioid Addiction, Chemsex, Alcoholism, and Smoking Among People Living With HIV

A CROI 2019 symposium demonstrated the need for continued research and programs that address substance use and its impact on people living with HIV.

By Sony Salzman

Not Surprisingly, PopART Study Showed Community-Based Services Reduce HIV Incidence

"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."

By David Barr

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

By Martha Kempner

Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid

Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.

By Stephen Hicks

People With HIV Have Substantially Higher Risk of Sudden Cardiac Death at Low CD4 Counts or Detectable Viral Load

New research involving veterans highlights the need to monitor HIV-positive patients for cardiovascular risk.

By Sony Salzman

Drug Use May Be Increasing Syphilis Rates Among HIV-Positive Cisgender Women, Studies Show

The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.

By Kenyon Farrow

Viral Reservoir Can Explain Persistent Low Level Viremia With Good Adherence on ART

A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.

By Simon Collins for HIV i-Base

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base